Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6920114 | 0.89 | HTR6 (0.38) | HTR6SIGMAR1MCHR1 | |
| SCHEMBL6920889 | 0.88 | PER2 (0.41) | HTR6 | |
| SCHEMBL6921529 | 0.86 | MAOA (0.39) | HTR6MCHR1 | |
| SCHEMBL6921471 | 0.86 | SIGMAR1 (0.43) | HTR6SIGMAR1MCHR1 | |
| SCHEMBL6920758 | 0.85 | HTR6 (0.36) | HTR6SIGMAR1MCHR1 | |
| SCHEMBL6919964 | 0.83 | HTR6 (0.35) | HTR6SIGMAR1MCHR1 | |
| SCHEMBL6920668 | 0.82 | HTR6 (0.33) | HTR6SIGMAR1MCHR1 | |
| SCHEMBL15290458 | 0.81 | HTR6 (0.40) | HTR6SIGMAR1MCHR1 | |
| SCHEMBL14729146 | 0.81 | SIGMAR1 (0.34) | HTR6SIGMAR1 | |
| SCHEMBL6920567 | 0.80 | HTR6 (0.31) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550782-B2 | Compounds and methods for treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9006263-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-8791132-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20140088086-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20130190294-A1 | COMPOUNDS AND METHODS FOR TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130053366-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053366-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | ADRB2, ADRA2B, ADRB1 | HTR6 47/4885SIGMAR1 761/4885MCHR1 88/4885 |
| US-20130190294-A1 | COMPOUNDS AND METHODS FOR TREATING DIABETES | ADRB2, ADRA2B, ADRA2C | HTR6 88/4885SIGMAR1 2010/4885MCHR1 124/4885 |
| US-20140088086-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | ADRB2, ADRA2B, ADRB1 | HTR6 47/4885SIGMAR1 761/4885MCHR1 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.